BioCentury
ARTICLE | Company News

CollabRx, Cynvenio Biosystems sales and marketing update

January 27, 2014 8:00 AM UTC

CollabRx launched its Therapy Finder for breast cancer patients who order Cynvenio's ClearID testing services. The launch extends the scope of a December deal to pair the CollabRx Genetic Variant Annotation (GVA) Service with tumor mutation profiling from whole blood provided by Cynvenio. CollabRx's breast cancer Therapy Finder is a web-based decision support tool that enables patients and their physicians to take into account the molecular aspects of a metastatic breast cancer tumor when determining a treatment plan. The partners could not be reached for details (see BioCentury, Dec. 23, 2013).

The GVA Service provides information on the clinical effect of specific genetic profiles and associated therapeutic strategies. Under the December deal, clinicians and researchers ordering genomic tests from Cynvenio will have the option to receive results along with GVA-based reporting. ...